Cingulate (CING) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special Meeting scheduled for August 23, 2024, to be held virtually for shareholder participation and voting.
Main agenda: approval of issuance of common stock underlying certain warrants and potential adjournment if more votes are needed.
Board recommends voting FOR both the Issuance Proposal and the Adjournment Proposal.
Voting matters and shareholder proposals
Shareholders to vote on authorizing issuance of shares underlying warrants, potentially exceeding 20% of outstanding stock, to comply with Nasdaq Listing Rule 5635(d).
Adjournment Proposal allows the meeting to be postponed if insufficient votes are received for the Issuance Proposal.
Board unanimously recommends approval of both proposals.
Stockholder proposals for the 2025 Annual Meeting must be received by December 27, 2024, for inclusion in proxy materials.
Board of directors and corporate governance
Board fixed June 28, 2024, as the record date for voting eligibility.
Only shareholders of record as of this date may vote; each share has one vote.
Quorum is one third of outstanding shares; abstentions and broker non-votes count toward quorum.
Latest events from Cingulate
- Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026 - Approval sought for stock issuance and board changes following a $12M private placement.CING
Proxy Filing2 Mar 2026 - Approval sought for major equity issuance and board changes following a $12M private placement.CING
Proxy Filing18 Feb 2026 - Biopharma targets ADHD market with $200M shelf registration amid financial uncertainty.CING
Registration Filing12 Jan 2026 - Registering 6.63M shares for resale tied to ADHD drug warrants, with proceeds for operations.CING
Registration Filing16 Dec 2025 - Proxy seeks approval for director, auditor, equity plan, and reverse split to support Nasdaq listing.CING
Proxy Filing2 Dec 2025